Prescription Drug Monitoring:

States Can Readily Identify Illegal Sales and Use of Controlled Substances

HRD-92-115: Published: Jul 21, 1992. Publicly Released: Jul 30, 1992.

Additional Materials:


Office of Public Affairs
(202) 512-4800

Pursuant to a congressional request, GAO provided information on state prescription drug monitoring programs, focusing on: (1) program benefits to investigations and their effectiveness in detecting and reducing drug diversion; (2) whether savings have resulted from reductions in Medicaid prescription drug claims; and (3) adverse effects on medical practice and patient care.

GAO found that: (1) prescription drug monitoring programs save investigators time, improve productivity, and allow identification of potential cases of drug diversion; (2) 5 of 10 states showed a reduction in the number of prescriptions due to reduced diversion or changes in physician prescribing practices; (3) states claim that prescription drug monitoring programs increase the efficiency of law enforcement operations and result in greater disciplinary action; (4) New York and Michigan estimated Medicaid cost savings at $27 million and $440,000, respectively, but a lack of complete data hampers Medicaid savings estimates and program tracking; (5) opponents believe that programs result in less effective drug prescription, compromise patient confidentiality, and change physicians' prescribing practices; and (6) three states utilize electronic transmission systems, which are viewed as less burdensome and less intrusive than multi-copy prescription form programs.

Oct 18, 2017

Oct 4, 2017

Oct 3, 2017

Sep 29, 2017

Sep 13, 2017

Sep 12, 2017

Sep 8, 2017

Sep 7, 2017

Looking for more? Browse all our products here